Cover Image
市場調查報告書

conoGenetix biosciences GmbH - 產品平台檢討

conoGenetix biosciences GmbH - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253750
出版日期 內容資訊 英文 19 Pages
訂單完成後即時交付
價格
Back to Top
conoGenetix biosciences GmbH - 產品平台檢討 conoGenetix biosciences GmbH - Product Pipeline Review - 2015
出版日期: 2015年04月29日 內容資訊: 英文 19 Pages
簡介

conoGenetix biosciences GmbH總公司設置於德國的生物製藥企業,正在開發自體免疫疾病用新胜肽治療藥。該公司產品有CGTX胜肽等針對多發性硬化症和類風濕性關節炎等各種自體免疫障礙的治療藥。除此以外,也提供胜肽的設計、電生理學性的實驗、增生分析和動物實驗及毒性實驗等。

本報告提供conoGenetix biosciences GmbH的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

conoGenetix biosciences GmbH的基本資料

  • conoGenetix biosciences GmbH概要
  • 主要資訊
  • 企業資料

conoGenetix biosciences GmbH:R&D概要

  • 主要的治療範圍

conoGenetix biosciences GmbH:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

conoGenetix biosciences GmbH:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

conoGenetix biosciences GmbH:藥物簡介

  • cgtx-A
  • cgtx-F
  • cgtx-G
  • Synthetic Peptide to Block Potassium Voltage-Gated Channel Subfamily A Member 3 (Kv1.3) for Autoimmune Disorders

conoGenetix biosciences GmbH:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

conoGenetix biosciences GmbH:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07034CDB

Summary

Global Markets Direct's, 'conoGenetix biosciences GmbH - Product Pipeline Review - 2015', provides an overview of the conoGenetix biosciences GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of conoGenetix biosciences GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of conoGenetix biosciences GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of conoGenetix biosciences GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the conoGenetix biosciences GmbH's pipeline products

Reasons to buy

  • Evaluate conoGenetix biosciences GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of conoGenetix biosciences GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the conoGenetix biosciences GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of conoGenetix biosciences GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of conoGenetix biosciences GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of conoGenetix biosciences GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • conoGenetix biosciences GmbH Snapshot
    • conoGenetix biosciences GmbH Overview
    • Key Information
    • Key Facts
  • conoGenetix biosciences GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • conoGenetix biosciences GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • conoGenetix biosciences GmbH - Pipeline Products Glance
    • conoGenetix biosciences GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • conoGenetix biosciences GmbH - Drug Profiles
    • cgtx-A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cgtx-F
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cgtx-G
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Block Potassium Voltage-Gated Channel Subfamily A Member 3 (Kv1.3) for Autoimmune Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • conoGenetix biosciences GmbH - Pipeline Analysis
  • conoGenetix biosciences GmbH - Pipeline Products by Target
  • conoGenetix biosciences GmbH - Pipeline Products by Molecule Type
  • conoGenetix biosciences GmbH - Pipeline Products by Mechanism of Action
  • conoGenetix biosciences GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • conoGenetix biosciences GmbH, Key Information
  • conoGenetix biosciences GmbH, Key Facts
  • conoGenetix biosciences GmbH - Pipeline by Indication, 2015
  • conoGenetix biosciences GmbH - Pipeline by Stage of Development, 2015
  • conoGenetix biosciences GmbH - Monotherapy Products in Pipeline, 2015
  • conoGenetix biosciences GmbH - Preclinical, 2015
  • conoGenetix biosciences GmbH - Discovery, 2015
  • conoGenetix biosciences GmbH - Pipeline by Target, 2015
  • conoGenetix biosciences GmbH - Pipeline by Molecule Type, 2015
  • conoGenetix biosciences GmbH - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • conoGenetix biosciences GmbH - Pipeline by Stage of Development, 2015
  • conoGenetix biosciences GmbH - Monotherapy Products in Pipeline, 2015
  • conoGenetix biosciences GmbH - Pipeline by Top 10 Target, 2015
  • conoGenetix biosciences GmbH - Pipeline by Top 10 Molecule Type, 2015
  • conoGenetix biosciences GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top